ClearSky Medical Diagnostics recently attended and exhibited at the 35th Global Conference of Alzheimer’s Disease International in June 2022.
The hybrid conference, hosted online and in-person at The Kia Oval in London, took place from 9 to 11 June 2022 with the theme of ‘new horizons in dementia’. In 2020, the conference attracted 1,600 delegates from 120 countries.
The conference addressed the progress and barriers, new developments and innovations across all seven action areas of the WHO Global action plan on dementia. It also looked at recent developments and forecast breakthroughs in research, diagnosis, treatment, care and support.
After successfully launching two CE-marked intelligent devices for Parkinson’s, ClearSky is now working on a new product, MCI-Monitor™ for objectively detecting mild cognitive impairment.
ClearSky’s initial studies have suggested that MCI-Monitor is able to differentiate between Parkinson’s with normal cognition, PD-MCI (Parkinson’s Disease MCI) and PDD (Parkinson’s Disease Dementia).
Professor Stephen Smith enjoyed successful meetings at ADI with our prototype device for detecting MCI generating keen interest.
ClearSky is now seeking partners to collaborate on the development and launch of MCI-Monitor to the general population – learn more about MCI-Monitor.